Concepedia

Rob Webster

RW

Statistics

Publications

22

Citations

2.3K

H-Index

17

Active since

2001

Affiliations

Pfizer (United Kingdom)(Current)

Pfizer (United States)

Rob Webster is an author at Pfizer (United Kingdom) specializing in pharmacology, pharmacy, and drug discovery.

Publications per year

2001–2018

22

Publications

22

Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity

Patrick Dorr, Mike Westby, Susan Dobbs et al. · Antimicrobial Agents and Chemotherapy · 2005 · 1.1K citations

Medicine, Medicinal Chemistry, Pharmacology +17

Prediction of Human Pharmacokinetics From Preclinical Information: Comparative Accuracy of Quantitative Prediction Approaches

Natilie Hosea, Wendy T. Collard, Susan Cole et al. · The Journal of Clinical Pharmacology · 2009 · 297 citations

Pharmacy, Pharmacokinetics, Pharmacology +15

A comprehensive non‐clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder

Ernesto Callegari, Bimal Malhotra, Peter J. Bungay et al. · British Journal of Clinical Pharmacology · 2011 · 181 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Towards a drug concentration effect relationship for QT prolongation and torsades de pointes.

Rob Webster, Derek J. Leishman, Don K. Walker · PubMed · 2002 · 116 citations

Medicine, Pharmacokinetics, Pharmacology +14

Pyrazole NNRTIs 4: Selection of UK-453,061 (lersivirine) as a Development Candidate

Charles E. Mowbray, Catherine Burt, Romuald Corbau et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 101 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +3

1–5 of 22